CASE REPORT article
Front. Med.
Sec. Dermatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1684204
This article is part of the Research TopicExploring Innovative Therapies for Rare Inflammatory Skin DiseasesView all 16 articles
Semaglutide in the Treatment of a Patient with Type 2 Diabetes Mellitus, Psoriasis, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Case Report
Provisionally accepted
- 900 Hospital of the Joint Logistics Team of the Chinese PLA, Fuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This case report highlights the therapeutic efficacy of semaglutide in a 49-year-old male with concurrent type diabetes mellitus (T2DM), psoriasis (PASI 22), and metabolic dysfunction-associated steatotic liver disease (MASLD). The patient presented with metabolic dysregulation, severe psoriatic lesions, and hepatic steatosis. Initial therapies, including acitretin and topical agents, failed to yield clinical improvement. Semaglutide was initiated at 0.25 mg/week, titrated to 1 mg/week over 12 weeks, alongside metformin dose adjustment. At 24 weeks, the patient exhibited significant improvements: HbA1c decreased from 9.8% to 7.2%, body weight reduced by 6 kg, liver enzymes returned to normal ranges, and PASI declined to 6.2. Treatment was well-tolerated with no severe adverse events.
Keywords: type 2 diabetes mellitus, Psoriasis, Semaglutide, A case report, Metabolic dysfunction-associated steatotic liver disease
Received: 12 Aug 2025; Accepted: 02 Sep 2025.
Copyright: © 2025 Lin, Huang, Weng and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lu Lin, 900 Hospital of the Joint Logistics Team of the Chinese PLA, Fuzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.